Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BKHA with free AI briefings, catalyst countdowns, and dilution alerts.

BKHA · Black Hawk Acquisition Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $7.20, 41% below $12.19, its close on the day of its Sep 24 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$12,052 Cash on Hand
0.3mo Cash Runway
Follow BKHA by email Get an email when BKHA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BKHA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Silevertinib Non-Small Cell Lung Cancer Phase 1/2 · NCT05256290 Active not recruiting
Use autologous cSVF + MSCs (cryo) for… Autism Spectrum Disorder Phase 1/2 · NCT07546942 Enrolling by invitation
Tuxobertinib (BDTX-189) Solid Tumor Phase 1 · NCT04209465 Terminated
Liberase Enzyme (Roche) Pulmonary Alveolar Proteinosis Early Phase 1 · NCT04326036 Unknown

Also used in these trials (approved or third-party drugs, not BKHA's own candidates): Temozolomide, Azathioprine, Carfilzomib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BKHA holds $12,052 in cash and short-term investments and burns about $140,017/quarter from operations, an estimated runway of 0.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BKHA files for a raise →

👥 Who Owns BKHA

Insiders 41.5% Other 5%+ holders 7.8% Institutions (23 holders) 50.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Black Hawk Management LLC
10% owner
Insider 1,725,000 41.53% 2024-04-04
W. R. Berkley Corporation 5%+ holder (13G) 322,086 7.75% 2026-09-30

Share count 4,153,577 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BKHA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BKHA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.